GCAN Greater Cannabis Company Inc (PK)

GammaCan International, Inc. (OTCBB: GCAN) today announced that physicians from Tel Ha'Shomer Hospital in Tel Aviv, and GammaCan will present top line findings of the GC 101 trial at the 5th Annual Congress on Autoimmunity taking place in Sorrento Italy from November 29th through December 3rd, 2006. The presentation and abstract are titled "Efficacy and Safety of IVIG Intravenous Immunoglobulin in Patients with Metastatic Melanoma." The senior authors are Drs. Jacob Schachter, MD and Uriel Katz, MD, PhD and the study was fully funded by GammaCan International, Inc. The researchers will present phase II clinical data examining the efficacy and safety of IVIG (GCAN101) in treating malignant, melanoma obtained from nine patients with metastatic disease who had failed all other modalities of therapy. Top line results suggest that IVIG may lead to stabilization of the disease in some patients and that IVIG therapy in patients with advanced malignant melanoma appears to be safe. Prof. Jacob Nusbacher, Director of Medical & Scientific Affairs at GammaCan commented: "This study is part of our larger GCAN 101 open label phase II study which also includes prostate and colon cancer patients. Unlike most other anti-cancer agents, IVIG has an excellent safety profile. Moreover, the results we see in melanoma are encouraging, particularly when one considers the advanced state of disease in the group of patients that were treated. These results give us further impetus to develop VitiGam, our next generation anti-melanoma immunoglobulin therapy." Data from the colon and prostate cancer arms will be published elsewhere. About GCAN101 GCAN101 (standard IgG) is currently completing an open label, 30 patient phase II trial designed to evaluate the efficacy and safety of IgG therapy in cancer patients who failed all current therapies. The trial is enrolling patients with colon cancer, melanoma and prostate cancer. The colon and melanoma arms are fully enrolled. About GammaCan GammaCan is focusing on the commercialization of an innovative anti-cancer immunotherapy to treat metastatic cancer. GammaCan's platform is based on IgG, a safe, relatively non-toxic human plasma-based product, currently used to treat a variety of immune deficiencies and autoimmune diseases. IgG works by strengthening the patient's immune system. Many experts currently view immunotherapy as a future alternative to today's standard chemotherapy. GammaCan is developing VitiGam, its second generation program. VitiGam is an IgG derived from the plasma of vitiligo donors and is being developed to treat malignant melanoma. GammaCan owns, and has applied for US patent protection covering the use of IgG and vitiligo-derived IgG (VitiGam). For more information about GammaCan visit www.GammaCan.com or call the company's headquarters in Kiryat Ono, Israel at +972 (03) 738-2616 or toll free 1-866-308-0396 (from North America). Safe Harbor Statement: Statements in this document that are not purely historical are forward-looking statements. Forward-looking statements in this release include statements regarding the commercialization of an anti-cancer immunotherapy and the Company developing the boosting of cancer patients' immune systems with IgG into an effective treatment. Actual outcomes and the Company's actual results could differ materially from those in such forward-looking statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the planned development of the technology, unforeseen technical difficulties in developing the technology, the inability to obtain regulatory approval for human use, competitors' therapies proving more effective, cheaper or otherwise preferable for consumers, inability to market the product we produce, among other factors, all of which could among other things, delay or prevent product release or cause our company to fail. For further risk factors see the risk factors associated with other early state medical research and development companies filed with the SEC on Edgar.